Table 1.
Patient characteristics at the time of metastasis
| Characteristic | Total (N=837) |
|---|---|
| Age at metastasis | |
| Median (IQR) | 76 (69,83) |
| Race | |
| Non-black | 605 (72%) |
| Black | 232 (28%) |
| Treatment center | |
| West LA | 154 (18%) |
| Palo Alto | 94 (11%) |
| San Francisco | 71 (8%) |
| Augusta | 68 (8%) |
| Durham | 157 (19%) |
| San Diego | 149 (18%) |
| Asheville | 46 (5%) |
| Portland | 98 (12%) |
| Biopsy grade group | |
| 1 | 109 (13%) |
| 2-3 | 171 (20%) |
| 4-5 | 249 (30%) |
| Unknown | 308 (37%) |
| Primary localized treatment | |
| None | 328 (39%) |
| RP ± XRT | 243 (29%) |
| XRT alone | 266 (32%) |
| Number of bone metastases | |
| 1 | 212 (25%) |
| 2 | 131 (16%) |
| 3-9 | 306 (37%) |
| ≥10 | 180 (22%) |
| Unknown | 8 (1%) |
| Lymph node metastasis | 109 (13%) |
| Visceral metastasis | 44 (5%) |
| PSA at metastasis | |
| Median (IQR) | 31.5 (12.0, 102.6) |
| PSADT at metastasis | |
| ≥9 months | 246 (29%) |
| <9 months | 442 (53%) |
| Unknown | 149 (18%) |
| Months from ADT to CRPC | |
| Median (IQR) | 42.0 (18.9, 74.4) |
| Months from CRPC to metastasis | |
| Median (IQR) | 15.1 (6.1, 31.7) |
| Bone pain | |
| No | 341 (41%) |
| Yes | 362 (43%) |
| Unknown | 134 (16%) |
| Follow-up | |
| Median (IQR) | 25.9 (12.0, 46.4) |
IQR: interquartile range